Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 3/20 | 0.60 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 8/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4582663 | 0.89 | PAK1 (0.55) | PAK1P2RX7KMT2AMEN1DRD4 | |
| SCHEMBL4582833 | 0.89 | PAK1 (0.55) | PAK1P2RX7KMT2AMEN1DRD4 | |
| SCHEMBL4019291 | 0.86 | PAK1 (0.63) | PAK1P2RX7KMT2AMEN1DRD4 | |
| Benzene SCHEMBL4019301 | 0.82 | PAK1 (0.54) | PAK1P2RX7KMT2AMEN1DRD4 | |
| SCHEMBL4024042 | 0.80 | PAK1 (0.71) | PAK1P2RX7KMT2AMEN1DRD4 | |
| SCHEMBL4020534 | 0.79 | PAK1 (0.65) | PAK1P2RX7KMT2AMEN1DRD4 | |
| SCHEMBL4018133 | 0.78 | PAK1 (0.72) | PAK1P2RX7KMT2AMEN1DRD4 | |
| SCHEMBL4020834 | 0.77 | PAK1 (0.60) | PAK1P2RX7KMT2AMEN1DRD4 | |
| SCHEMBL4017222 | 0.76 | PAK1 (0.56) | PAK1P2RX7KMT2AMEN1DRD4 | |
| SCHEMBL4024845 | 0.76 | DRD2 (0.61) | PAK1P2RX7KMT2AMEN1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-06-19 | — | — | US | claimed |
| EP-1900731-A1 | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides as EP2-receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2008028689-A1 | N-(1-PHTHALAZIN-1-YLPIPERIDIN-4-YL)AMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | claimed |
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-06-19 | — | — | US | disclosed |
| EP-1900731-A1 | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides as EP2-receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008028689-A1 | N-(1-PHTHALAZIN-1-YLPIPERIDIN-4-YL)AMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | PTGER2, PTGER1, PTGDR2 | PAK1 1508/4885P2RX7 146/4885KMT2A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.